Neurosurgery for chronic neuropathic pain - Hindawi

Color profile: EMBASSY.CCM - Scitex Scitex Composite Default screen

NEUROLOGY AND CHRONIC PAIN 100

100

95

95

75

75

25

25

Neurosurgery for chronic neuropathic pain

5

0

5

0

Jung Y Park MD PhD1,2, Andres M Lozano MD PhD FRCSC1,2

JY Park, AM Lozano. Neurosurgery for chronic neuropathic pain. Pain Res Manage 2000;5(1):101-106.

La neurochirurgie pour la douleur neuropathique chronique RÉSUMÉ : La neurochirurgie peut jouer un rôle dans la prise en charge des patients souffrant d’une douleur neuropathique chronique réfractaire. Cependant, la sélection des patients comme candidats à la chirurgie et le choix de l’intervention chirurgicale la mieux appropriée restent un défi, et les interventions chirurgicales ont souvent une efficacité limitée. Si l’on envisage une chirurgie, les interventions qui ont un effet neuromodulateur ou neuroamplificateur (par exemple, une stimulation cérébrale profonde, ou celle du cortex moteur ou une stimulation spinale ou bien périphérique) sont généralement préférables à des méthodes ablatives comme méthodes de premier choix. Avec une meilleure compréhension des mécanismes de la douleur, la chirurgie aura plus à offrir aux patients atteints d’une douleur neuropathique chronique.

Neurosurgery can play a role in the management of patients with refractory chronic neuropathic pain. However, selecting patients as candidates for surgery and choosing the most appropriate surgical procedure is challenging, and surgical interventions often have limited efficacy. When considering surgery, neuroaugmentative or neuromodulative procedures (eg, peripheral, spinal, motor cortex or deep brain stimulation) are generally preferred over ablative procedures as initial modalities. With better understanding of specific pain mechanisms, surgery will have more to offer patients with chronic neuropathic pain. Key Words: Chronic neuropathic pain; Surgery

C

100

95

75

25

5

of neural injury. It is classified as ‘peripheral type’ when it results from neural injury or dysfunction from peripheral sources or as ‘central type’, when it arises from dysfunction in the brain and spinal cord. Neuropathic pain, in contrast to somatic or nociceptive pain, usually occurs without ongoing physiological activation of nociceptors. However, neuropathic and nociceptive pain may have overlapping features, and both types may at times be complicated by psychological and psychosocial factors. Table 1 lists the broad range of causes of peripheral and central neuropathic pain. Only patients with chronic neuropathic pain that fails to respond to medical treatment are considered potential candidates for surgical treatment. Hence, neurosurgeons are called upon to treat these often difficult pain syndromes. The goal here is to describe neurosurgical treatments for the chronic, intractable neuropathic pain states and to provide a brief outline of current neurosurgical approaches in these settings.

hronic pain has been defined as pain that lasts longer than three to six months or, as proposed by the International Association for the Study of Pain. It is pain that outlasts the period of normal healing of an acute abnormality (1). Any acute pain has the potential to become chronic, and this conversion can follow different temporal courses for different problems. Pain of primarily neural origin is termed neuropathic pain. Common features of chronic neuropathic pain include spontaneous burning, paroxysmal jabbing or shocking pain, hyperpathia, hyperalgesia, and allodynia or touch-evoked pain. These features may occur alone or in combination. Causes of neuropathic pain include injuries to the nervous system, whether by trauma, ischemia or metabolic dysfunction. Neuropathic pain is idiosyncratic; not every patient who suffers neural injury develops this type of pain. The incidence of neuropathic pain may also vary according to the site

Toronto Western Hospital, University of Toronto, Toronto, Ontario Correspondence and reprints: Dr Andres M Lozano, 1The Toronto Hospital, Western Division, McLaughlin Pavilion 2-433, 399 Bathurst Street, Toronto, Ontario M5T 2S8. Telephone 416-603-6200, fax 416-603-5298, e-mail [email protected]

100

95

75

25

5

0

0

Pain Res Manage Vol 5 No 1 Spring 2000

101 1

G:\PAIN\2000\5#1\Park\Park.vp Tue Apr 18 15:56:50 2000


Park and Lozano 100

95

75

25

5

0

100

TABLE 1 Various types of peripheral and central neuropathic pain Peripheral neuropathic pain Peripheral nerve injury with or without sympathetically maintained pain Complex regional pain syndromes (reflex sympathetic dystrophy or causalgia) Carpal tunnel syndrome Meralgia paresthetica Diabetic neuropathy Failed back surgery syndrome or postlaminectomy syndrome Trigeminal neuralgia or trigeminal neuropathic pain Glossopharyngeal neuralgia Postherpetic neuralgia Occipital neuralgia Brachial plexus neuropathy or avulsion

95

Central neuropathic pain

75

Pain of spinal cord origin Trauma Inflammation (eg, myelitis)

25

Tumour 5

Vascular pain (eg, Wallenberg’s syndrome)

0

Iatrogenic pain (postcordotomy dysesthesia) Other (eg, syringomyelia) Pain of brain stem origin Syringobulbia Multiple sclerosis (symptomatic trigeminal neuralgia) Thalamus (ventroposterior thalamus) Stroke, tumour, abscess Cortical or subcortical pain Stroke, tumour

Incisional neuralgia Phantom pain

100

95

75

25

5

Detailed review is not intended, but rather an attempt is made to establish a framework within which the practising clinician can add insights when providing care to these patients.

Figure 1) Postoperative thoracolumbar spine x-ray showing spinal cord stimulation electrode with four contacts on T10-11 epidural space. Reproduced with permission from Medtronic Inc, Minneapolis

SURGICAL TREATMENT OF CHRONIC NEUROPATHIC PAIN Before considering any surgical measure to treat patients with chronic neuropathic pain, appropriate medical therapeutic approaches should be thoroughly investigated and exhausted. Generally, when neurosurgical therapy is considered, neuroaugmentative or neuromodulative procedures are preferred over ablative approaches as the initial surgical modality. This is because of their reversibility and low incidence of significant side effects. These approaches are only undertaken after the primary and causative disturbances, for example compression, tumours, infections and ongoing mechanical injury, etc, have been addressed. Pain associated with peripheral nerve abnormalities that is located primarily in the distribution of a single peripheral nerve may be treated with peripheral nerve stimulation (PNS) (2). The mechanism of action of PNS may be central or peripheral. As with other pain control operations, there must be a clear cut etiology for the pain, and a correctable pathology (eg, nerve entrapment syndrome) should be excluded. The surgery is usually done in two phases. Usually, a site proximal to the injury site is selected for electrode placement. After a skin incision and dissection to free 5 to 6 cm of nerve, the electrode is placed directly under the nerve and sutured in place. The electrode lead is then externalized through a small stab wound and connected to a temporary electrical stimulator. The effects of stimulation through the implanted electrode are evaluated over this trial phase, which

can last two to three days. The settings of the temporary stimulator are considered satisfactory when the patient reports a fine tingling sensation in the nerve distribution. There are two potential outcomes of this trial. In patients where stimulation does not help the pain, the device is removed. On the other hand, patients who derive substantial pain relief, usually greater than 50% on a pain visual analogue scale, go on to permanent implantation in which the stimulating electrode is connected to a battery powered, pacemaker-like, implanted pulse generator. Results from a large series (3) indicated good to excellent pain relief in 70% to 80% of patients. These devices, like all stimulation implants, are subject to displacement, infection, breakage of leads and loss of battery power over time. Peripheral nerve pain from multiple sources, including neuropathic pain secondary to neural injury as a consequence of degenerative disc disease, postamputation pain (eg, phantom limb pain, stump pain), reflex sympathetic dystrophy (now replaced with the term ‘complex regional pain syndrome’ [CRPS] type 1), or causalgia (CRPS type 2), may be relieved by spinal cord stimulation (SCS) (4,5) (Figure 1). A relevant animal model of chronic neuropathic pain, showing apparent relief by SCS, has been developed recently (6). Its exact mechanism of action of SCS is not fully understood but may at least partly be mediated via GABAergic and adenosine-dependent mechanisms, or modulated by influencing the transmission of A fibres and not of c fibres. Some effects of SCS may be mediated by the sympathetic nervous

0

100

95

75

25

5

0

102

Pain Res Manage Vol 5 No 1 Spring 2000 2



Surgery for chronic neuropathic pain 100

95

75

25

5

0

100

95

75

25

5

100

system. The development of percutaneous placement of electrode arrays and of improved programmable implanted electronics have been major technical advances in the application of SCS in patients with intractable neuropathic pain. A temporary, percutaneous electrode is first placed in the patient under local anesthesia and connected to a temporary stimulation device either in a fluoroscopy suite or operating room. A permanent implant with pulse generator may be introduced to the patient if satisfactory pain results are obtained during the trial period. Both percutaneous and laminectomy designs for SCS electrodes are available. The success rates reported in the literature on SCS have varied widely, but recent long term follow-up studies based on third party evaluations indicate 52% to 66% good to excellent results (7,8). As with PNS, SCS has the inherent advantage of a low morbidity trial or test phase that is used as a predictor of the long term effect. Although intraspinal analgesic therapy is considered to be more effective for nociceptive than for neuropathic pain, if PNS or SCS is unsuccessful or inappropriate, a trial of intraspinal analgesic therapy may be warranted. The role of intraspinal (ie, intrathecal or epidural) infusion therapy in cases of intractable neuropathic pain is not fully established, but up to 50% of patients with neuropathic pain may be improved by intrathecal or epidural analgesic substances (9,10). Despite the relative insensitivity of these pain states to systemic narcotics, significant relief has been observed in some patients by using intraspinal narcotics. Moreover, the risk of becoming dependent or addicted to these agents from long term use seldom exists. Other drugs such as clonidine and adenosine in intraspinal use are also reported to be effective in refractory cases (11-13). However, these agents and other newly introduced drugs are still considered investigational for this application. Deep brain stimulation (DBS) (Figure 2) may be appropriate for some patients with intractable neuropathic pain, especially when other neuroaugmentation therapies fail. Theoretically, pain may be modulated by stimulation or lesioning of any of the following structures or regions of brain related to ascending or descending pain pathways: periaqueductal grey (PAG)/periventricular grey (PVG) region, thalamus, internal capsule and medial lemniscus. Although the mechanisms underlying the effects of DBS are not established, possible mechanisms may involve opiate mediation and activation of descending inhibitory pathways for PVG/PAG stimulation (14), and inhibition of spinothalamic neurons in dorsal horn or blockage of disrupted activity in various thalamic nuclei (15,16). DBS has the potential to treat chronic pain of any etiology, in any location. However, its success rate varies according to the nature of pain, the site of stimulation and the criteria used to define success. The range of success is typically from 30% to 70% (17,18). This technique is not widely available, and as with other surgically implanted pain therapies it remains expensive. Recommended brain targets for DBS electrode implantation to treat central pains related to deafferentation or neuropathic pain (eg, anesthesia dolorosa, postcordotomy

95

75

25

5

0

Figure 2) Configuration of implanted brain electrode and connections to remainder of deep brain stimulation equipment (top) and magnetic resonance imaging after implantation of a thalamic deep brain stimulation electrode (bottom). Reproduced with permission from Medtronic Inc, Minneapolis, Minnesota

dysesthesia, thalamic syndrome, brachial plexus avulsion, postherpetic neuralgia, and spinal and peripheral nerve injuries) are thalamic sensory relay nuclei, ventral posterior lateral or ventral posterior medial, and the medial lemniscus or internal capsule (19). However, implantation of electrodes on the PVG region may be more suitable for patients with nociceptive pain when other measures fail. Electrodes are implanted stereotactically when the patient is under local anesthesia supplemented as necessary by intravenous midazolam and/or fentanyl. Electrodes are introduced according to anatomical targets, based on preoperatively obtained anterior commissure and posterior com-

0

100

95

75

25

5

0


103 3



Park and Lozano 100

100

except that mapping of the motor cortex is necessary by intraoperative somatosensory-evoked potentials. Although this technique is not widely investigated, it appears to be a new and promising possibility of pain treatment, especially in cases with chronic, refractory neuropathic pain. Ablative procedures in the spinal cord such as cordotomy have been used in some patients with intractable nonmalignant pain but are known to be more effective in nociceptive pain than in neuropathic pain conditions. Cordotomy is seldom used to treat disorders, except malignant diseases, because of concern about the development of postcordotomy dysesthesia or fading of the level of pain relief with time. Dorsal root entry zone (DREZ) lesions, however, can be uniquely effective in select cases of intractable neuropathic pain, including roots or plexus avulsions and postparaplegic pain, with long term success rates often greater than 50%. The segmental, end zone pain of spinal cord injury may also respond to DREZ lesions; the more diffuse, distal pain following spinal cord injury tends to be refractory. Also, it is not as successful for the treatment of postamputation stump pain (25). DREZ destroys the dorsal horn (including substantia gelatinosa), Lissauer’s tract, and the adjacent portion of the posterior and lateral funiculi, thus inhibiting incoming nociceptive inputs and modulating signals descending via the Raphe spinal, reticulospinal and cortical spinal tracts. After laminectomy and dural opening at appropriate levels have been achieved under general anesthesia, the electrode is introduced to a depth of 2 mm, and the lesion is generally made by heating the radio frequency (RF) electrode tip to 75°C and holding the temperature for 15 s. Successive lesions are spaced 2 mm apart, and spinal cord function is monitored by using somatosensory- and motor-evoked potential during the operation. In summary, pain recalcitrant to conventional therapy, in cases of neuropathic pain due to brachial plexus injury, is seen in about one-third of patients and causes significant disability. DREZ lesions mitigate this pain in approximately 60% of patients (26). In addition, although up to 50% of patients experience some neurological deficits following surgery, this occasionally results in worsening of functional impairment. Intracranial ablative procedures, including medial thalamotomy, mesencephalic tractotomy, anterior capsulotomy, hypophysectomy and cingulotomy, have been used primarily in terminally ill patients with cancer-related pain. However, these procedures have often been associated with recurrence or worsening of pain after the procedure. Cingulotomy lesions neurons and interrupts the Papez circuit of the limbic system; its target is the anterior cingulated gyrus, caudal portion, area 24. The recommended target for thalamotomy is the medial thalamus, involving the central lateral or parafascicular nucleus (27). The results, however, do not seem to be as good as those of DBS and are usually short lived. Overall, these procedures have limited indications, are used infrequently and are not generally applicable to patients with chronic neuropathic pain. However, with improved stereotactic techniques guided by better imaging systems, refined microelectrode recordings and stimulation techniques; rela-

95

75

25

5

0

Figure 3) Postoperative skull x-ray showing electrodes placed on motor cortex for chronic stimulation

100

95

75

25

5

missure coordinates from stereotactic magnetic resonance images. Intraoperative physiological studies such as single unit microelectrode recording, and micro- and macrostimulation techniques greatly enhance the correct targeting before implantation of the electrode. A trial stimulation period of two to seven days is carried out. If significant pain relief ensues, the electrode is connected either to a radiofrequency receiver or to a fully implanted pulse generator for chronic stimulation. The internalization procedure, which is done under short general anesthesia, involves connecting the electrode to a pulse generator subcutaneously, usually in the subclavicular area. Although nociceptive pain is known to respond better to DBS, about 30% to 60% of patients with neuropathic pain are expected to have long term pain relief from DBS (8,17). However, DBS is among the most invasive techniques available and is associated with substantial morbidity. The incidence of minor complications (electrode dislodgement, breakage, skin erosion infection) is approximately 10%, while the incidence of serious neurological complications including intracerebral hemorrhage leading to permanent neurological deficit is 2% to 3% with these procedures. Other areas of the brain have been studied for stimulation-induced analgesia and pain relief for neuropathic pain. In particular, chronic stimulation of the motor cortex (Figure 3) has recently gained attention. Favourable results have been reported for intractable central and neuropathic pain of peripheral origin including thalamic pain, trigeminal neuropathic pain, postherpetic neuralgia pain, bulbar pain of Wallenberg syndrome, and pain from peripheral nerve or spinal cord injuries (20-24). Again, the therapeutic mechanism underlying motor cortex stimulation is unclear, but it has been proposed that precentral stimulation activates nonnociceptive neurons in the sensory cortex, which may then act to inhibit presumed hyperactive nociceptive cortical neurons (24). The surgical procedure is similar to that of DBS,

0

95

75

25

5

0

100

95

75

25

5

0

104




Surgery for chronic neuropathic pain 100

95

75

25

5

0

100

tively low morbidity; lower cost than that of augmentative procedures; and lack of need for general anesthesia, they may be suitable in certain circumstances. Generally, patients with trigeminal neuralgia are managed by medical treatment. However, up to 30% of patients will ultimately require more aggressive therapy. There are two common mainstays of surgical therapy for these patients (ie, percutaneous trigeminal gangliolysis and microvascular decompression), both with similar high success rates (70% to 90%) of long lasting or even permanent pain relief (28-30). Recently, radiosurgery with gamma knife for chronic pain has been used by several investigators with some promising results (31-34). The role of radiosurgery in disorders such as trigeminal neuralgia is being studied (35,36). Although it is a noninvasive procedure to the brain, it may produce unpredictably large lesions, and until well-designed, long term follow-up studies are available, this technique remains speculative.

choice of the surgical procedure should be carefully decided based on diligent evaluation. Some surgical interventions have substantial potential morbidity, and this must be considered before deciding to operate. Also, no one neurosurgical procedure can relieve the pain complaints of all patients, and surgery performed because there is ‘nothing left to try’ is most likely to fail. Whichever procedure is chosen or intended, treating neurosurgeons should have the necessary neuroscience background and surgical skills to be an important member of the team caring for these multifaceted, chronically ill patients. Neurosurgical strategies will be more diverse, and neurosurgery will likely offer better and more options for the management of chronic neuropathic pain syndromes in the future. These strategies will be driven by a better understanding of basic pathophysiological mechanisms underlying neuropathic pain. Animal models of chronic neuropathic pain are available to test novel strategies. Further, the available surgical procedures (eg, SCS, DBS and chronic cortical stimulation) are being refined and will be more widely available. Other promising modes of therapies (eg, transplantation, gene therapy) are also being intensely investigated. Advances in these surgical and pharmacological strategies will make a significant impact on the treatment of pain of neural origin.

CONCLUSIONS The main challenge facing the treatment of neuropathic pain is the incomplete understanding of its pathogenesis and consequently the limited success of its treatment. The selection of patients who are likely to respond to surgery and the

95

75

25

5

0

REFERENCES

100

95

75

25

5

13. Middleton JW, Siddall PJ, Walker S, Molloy AR, Rutkowski SB. Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study. Arch Phys Med Rehabil 1996;77:824-6. 14. Gybels JM, Sweet WH. Neurosurgical Treatment of Persistent Pain. Physiological and Pathological Mechanisms of Human Pain, vol 11. Basel Karger, 1989. 15. Gerhart KD, Yezierski RP, Fang ZR, Willis WD. Inhibition of primate tract neurons by stimulation in ventral posterior lateral (VPLc) thalamic nucleus: possible mechanims. J Neurophysiol 1983;49:406-23. 16. Lenz FA. The ventral posterior nucleus of thalamus is involved in the generation of central pain syndromes. Am Pain Soc J 1992;1:42-51. 17. Levy RM, Lamb S, Adams JE. Treatment of chronic pain by deep brain stimulation: long term follow-up and review of the literature. Neurosurgery 1987;21:885-93. 18. Tasker RR, Vilela Filho O. Deep brain stimulation for neuropathic pain. Stereotact Funct Neurosurg 1995;65:122-4. 19. Young RF, Rinaldi PC. Brain stimulation. In: North RB, Levy RM, eds. Neurosurgical Management of Pain. New York: Springer-Verlag, 1997:283-301. 20. Katayama Y, Tsubokawa T, Yamamoto T. Chronic motor cortex stimulation for central deafferentation pain: experience with bulbar pain secondary to Wallenberg syndrome. Stereotact Funct Neurosurg 1994;62:295-9. 21. Nguyen JP, Keravel Y, Feve A, et al. Treatment of deafferentation pain by chronic stimulation of the motor cortex: report of a series of 20 cases. Acta Neurochir Suppl (Wien) 1997;68:54-60. 22. Meyerson BA, Lindblom U, Linderoth B, Lind G, Herregodts P. Motor cortex stimulation as treatment of trigeminal neuropathic pain. Acta Neurochir Suppl (Wien) 1993;58:150-3. 23. Nguyen JP, Lefaucheur JP, Decq P, et al. Chronic motor cortex stimulation in the treatment of central and neuropathic pain. Correlations between clinical, electrophysiological and anatomical data. Pain 1999;82:245-51. 24. Tsubokawa T, Katayama Y, Yamamoto T, Hirayama T, Koyama S.

1. Bonica JJ. Definitions and taxonomy of pain. In: Bonica J, Loeser JD, Chapman CR, Fordyce WE, eds. The Management of Pain. Philadelphia: Lea & Febiger, 1990:18-27. 2. Hassenbusch SJ, Stanton-Hicks M, Schoppa D, Walsh JG, Covington EC. Long-term results of peripheral nerve stimulation for reflex sympathetic dystrophy. J Neurosurg 1996;84:415-23. 3. Shetter AG, Racz GB, Lewis R, Heavner JE. Peripheral nerve stimulation. In: North RB, Levy RM, eds. Neurosurgical Management of Pain. New York: Springer-Verlag, 1997:261-70. 4. Barolat G, Singh-Sahni K, Staas WE Jr, Shatin D, Ketcik B, Allen K. Epidural spinal cord stimulation in the management of spasms in spinal cord injury: a prospective study. Stereotact Funct Neurosurg 1995;64:153-64. 5. North RB, Roark GL. Spinal cord stimulation for chronic pain. Neurosurg Clin N Am 1995;6:145-55. 6. Meyerson BA, Ren B, Herregodts P, Linderoth B. Spinal cord stimulation in animal models of mononeuropathy: effects on the withdrawal response and the flexor reflex. Pain 1995;61:229-43. 7. North RB, Kidd DH, Zahurak M, James CS, Long DM. Spinal cord stimulation for chronic, intractable pain: experience over two decades. Neurosurgery 1993;32:384-94. 8. Kumar K, Toth C, Nath RK. Deep brain stimulation for intractable pain: a 15-year experience. Neurosurgery 1997;40:736-46. 9. Penn RD. Intrathecal drug infusion for pain. In: Youmans JR, ed. Neurological Surgery. Philadelphia: WB Sounders, 1996:3552-9. 10. Hassenbusch SJ, Stanton-Hicks M, Covington EC, Walsh JG, Guthrey DS. Long-term intraspinal infusions of opioids in the treatment of neuropathic pain. J Pain Symptom Manage 1995;10:527-43. 11. Glynn C, O’Sullivan K. A double-blind randomised comparison of the effects of epidural clonidine, lignocaine and the combination of clonidine and lignocaine in patients with chronic pain. Pain 1996;64:337-43. 12. Gomes JA, Li X, Pan HL, Eisenach JC. Intrathecal adenosine interacts with a spinal noradrenergic system to produce antinociception in nerve-injured rats. Anesthesiology 1999;91:1072-9.

0

100

95

75

25

5

0


105 5



Park and Lozano 100

100

95

75

25.

26. 25

5

27. 0

28.

29.

30.

Chronic motor cortex stimulation in patients with thalamic pain. J Neurosurg 1993;78:393-401. Rosomoff HL, Papo I, Loeser JD. Neurosurgical operations of the spinal cord. In: Bonica J, Loeser JD, Chapman CR, Fordyce WE, eds. The Management of Pain. Philadelphia: Lea & Febiger, 1990:2067-81. Nashold BS, Friedman AH, Sampson JH, Nashold JRB, El-Naggar AO. Dorsal root entry zone lesions for pain. In: Youmans JR, ed. Neurological Surgery. Philadelphia: WB Sounders, 1996:3452-62. Davis KD, Lozano AM, Tasker RR, Dostrovsky JO. Brain targets for pain control. Stereotact Funct Neurosurg 1998;71:173-9. Lovely TJ, Jannetta PJ. Microvascular decompression for trigeminal neuralgia. Surgical technique and long-term results.Neurosurg Clin N Am 1997;8:11-29. Burchiel KJ, Clarke H, Haglund M, Loeser JD. Long-term efficacy of microvascular decompression in trigeminal neuralgia. J Neurosurg 1988;69:35-8. Burchiel KJ, Steege TD, Howe JF, Loeser JD. Comparison of percutaneous radiofrequency gangliolysis and microvascular

31.

32.

33.

34. 35.

36.

decompression for the surgical management of tic douloureux. Neurosurgery 1981;9:111-9. Kondziolka D, Lunsford LD, Flickinger JC, et al. Stereotactic radiosurgery for trigeminal neuralgia: a multiinstitutional study using the gamma unit. J Neurosurg 1996;84:940-5. Pollock BE, Gorman DA, Schomberg PJ, Kline RW. The Mayo Clinic gamma knife experience: indications and initial results. Mayo Clin Proc 1999;74:5-13. Young RF, Vermeulen SS, Grimm P, et al. Gamma knife thalamotomy for the treatment of persistent pain. Stereotact Funct Neurosurg 1995;64:172-81. Lindquist C, Kihlstrom L. Department of Neurosurgery, Karolinska Institute: 60 years. Neurosurgery 1996;39:1016-21. Young RF, Vermulen S, Posewitz A. Gamma knife radiosurgery for the treatment of trigeminal neuralgia. Stereotact Funct Neurosurg 1998;70(Suppl 1):192-9. Kondziolka D, Lunsford LD, Flickinger JC. Gamma knife radiosurgery as the first surgery for trigeminal neuralgia. Stereotact Funct Neurosurg 1998;70(Suppl 1):187-91.

95

75

25

5

0

100

100

95

95

75

75

25

25

5

5

0

0

106



MEDIATORS of

INFLAMMATION

The Scientific World Journal Hindawi Publishing Corporation http://www.hindawi.com

Volume 2014

Gastroenterology Research and Practice Hindawi Publishing Corporation http://www.hindawi.com

Volume 2014

Journal of

Hindawi Publishing Corporation http://www.hindawi.com

Diabetes Research Volume 2014


Volume 2014


Volume 2014

International Journal of

Journal of

Endocrinology

Immunology Research Hindawi Publishing Corporation http://www.hindawi.com

Disease Markers


Volume 2014

Volume 2014

Submit your manuscripts at http://www.hindawi.com BioMed Research International

PPAR Research Hindawi Publishing Corporation http://www.hindawi.com


Volume 2014

Volume 2014

Journal of

Obesity

Journal of

Ophthalmology Hindawi Publishing Corporation http://www.hindawi.com

Volume 2014

Evidence-Based Complementary and Alternative Medicine

Stem Cells International Hindawi Publishing Corporation http://www.hindawi.com

Volume 2014


Volume 2014

Journal of

Oncology Hindawi Publishing Corporation http://www.hindawi.com

Volume 2014


Volume 2014

Parkinson’s Disease

Computational and Mathematical Methods in Medicine Hindawi Publishing Corporation http://www.hindawi.com

Volume 2014

AIDS

Behavioural Neurology Hindawi Publishing Corporation http://www.hindawi.com

Research and Treatment Volume 2014


Volume 2014


Volume 2014

Oxidative Medicine and Cellular Longevity Hindawi Publishing Corporation http://www.hindawi.com

Volume 2014